



WESTMINSTER
HEALTH FORUM

The future of biosimilars in the UK: regulation, access and medicines optimisation 15th June 2017

Seminar supported by **Sandoz Ltd**

SANDOZ A Novartis
Division

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

Contents

<u>About this Publication</u>	3
<u>Agenda</u>	4
<u>Session Chair's opening remarks</u>	
Angela McFarlane , Market Development Director, QuintilesIMS (<i>transcript</i>)	6
<u>Key issues in the development of biosimilars: research, intellectual property and competition</u>	
Tim de Gavre , Chair, British Biosimilars Association and Country Head, Sandoz Ltd (<i>transcript</i>)	8
Harriet Lewis , NHS Engagement Partner and Programme Lead, Medicines Optimisation, ABPI (<i>transcript</i>)	11
Natasha Pearman , Managing Associate, Mishcon de Reya (<i>transcript</i>)	14
Dr Matt Cooper , Business Development and Marketing Director, NIHR Clinical Research Network (<i>transcript</i>)	17
Questions and comments from the floor (<i>transcript</i>)	20
<u>Session Chair's closing remarks</u>	
Angela McFarlane , Market Development Director, QuintilesIMS (<i>transcript</i>)	26
<u>Session Chair's opening remarks</u>	
Daniel Zeichner MP (<i>transcript</i>)	27
<u>Challenges for market access, value and the appraisal process</u>	
Jonathan Underhill , Medicines Clinical Adviser, Medicines and Prescribing Programme, NICE (<i>transcript</i>)	28
Dr Anant Jani , Executive Director, Better Value Healthcare and Honorary Research Fellow, University of Oxford (<i>transcript</i>)	32
Questions and comments from the floor (<i>transcript</i>)	34
<u>Bringing biosimilars into service delivery: commissioning, patient involvement and manufacturing</u>	
Angela McFarlane , Market Development Director, QuintilesIMS (<i>transcript</i>)	41
James Kent , Medicines Procurement Specialist - London and East of England, Specialist Pharmacy Service (<i>transcript</i>)	44
Professor Jayne Lawrence , Chief Scientist, Royal Pharmaceutical Society and Professor of Biophysical Pharmaceutics, King's College London (<i>transcript</i>)	48
Dr Fraser Cummings , Consultant Gastroenterologist, University Hospital Southampton NHS Foundation Trust (<i>Text removed at speaker's request</i>)	51
Helen Terry , Director of Policy, Public Affairs and Research, Crohn's and Colitis UK (<i>transcript</i>)	52
Questions and comments from the floor (<i>transcript</i>)	55
<u>Session Chair's and Westminster Health Forum closing remarks</u>	
Daniel Zeichner MP (<i>transcript</i>)	58
Matthew Bradberry , Forum Lead, Westminster Health Forum (<i>transcript</i>)	59
<u>Comments</u>	60
<u>List of Delegates Registered for Seminar</u>	63
<u>Contributor Biographies</u>	69
<u>About the sponsor</u>	70
<u>About the Core Sponsors of the Westminster Health Forum</u>	71

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

About this Publication

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: The future of biosimilars in the UK: regulation, access and medicines optimisation held on 15th June 2017. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796
F: 01344 420121
publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder
Chris Whitehouse